AngioDynamics, Inc. — Form 10-Q Summary
Reporting period: First quarter of fiscal 2024, the three months ended August 31, 2023. Comparative figures are for the three months ended August 31, 2022. The company reports two segments: Med Tech and Med Device.
Financial performance
| Metric | Q1 FY2024 | Q1 FY2023 |
|---|---|---|
| Net sales | $78.7 million | $81.5 million |
| Gross profit / margin | $40.1 million / 50.9% | $42.3 million / 51.9% |
| Operating income (loss) | $35.0 million | $(13.3) million |
| Net income (loss) | $45.9 million | $(13.0) million |
| Diluted EPS | $1.15 | $(0.33) |
| Cash used in operating activities | $25.9 million | $24.7 million |
- Revenue declined 3.5%. Med Tech sales rose 13.3% to $25.9 million; Med Device sales fell 10.0% to $52.8 million.
- Med Tech gross margin improved to 64.7% from 63.2%; Med Device gross margin decreased to 44.2% from 47.5%.
- Net income included a $47.8 million pretax gain on the sale of the dialysis and BioSentry businesses. The sale also generated $100.0 million in cash proceeds; it was not classified as discontinued operations.
- Cash and cash equivalents were $57.6 million at August 31, 2023, compared with $44.6 million at May 31, 2023. Investing activities provided $98.4 million, largely from the divestiture; financing activities used $59.6 million, including repayment of $50.0 million of debt and a $10.0 million contingent-consideration payment.
- No debt was outstanding at quarter-end; the credit agreement was extinguished after the divestiture. Current liabilities were $57.5 million. Contingent consideration was $9.2 million, down from $19.3 million at May 31.
Changes and management commentary
- The divested businesses reduced year-over-year sales by approximately $7.1 million and gross profit by approximately $4.2 million. Excluding that comparison effect, the filing attributes segment movements to product-level changes and other operating factors.
- Med Tech growth reflected higher Auryon and NanoKnife sales, partly offset by softness in thrombus management. Med Device declines were primarily related to the divestiture, with some declines in PICCs, core and other oncology, and vascular access products.
- Management cited raw-material, labor and freight inflation, labor shortages, supply-chain reliability and backlog as ongoing pressures. Backlog was $3.3 million, up $0.6 million from May 31.
- Management said current cash, together with expected operating cash generation, should meet anticipated capital needs for at least 12 months. The company may need external financing for future cash acquisitions or if circumstances materially change.
- The filing gives no specific numerical earnings or revenue guidance. Management describes growth and profitability ambitions through geographic expansion, new products, market penetration and international growth.
Risks, contingencies and unusual items
- Reported earnings were materially affected by the divestiture gain and an $11.0 million income tax benefit. The company cites a valuation allowance, foreign taxes and nondeductible items as factors affecting its tax rate; it says it has not yet attained sustained profitability and will continue to assess the allowance.
- Cash used in operations exceeded net income, in part because of working-capital movements, including a $16.5 million decrease in accounts payable, accrued and other liabilities and increases in inventory and prepaid expenses.
- Bard patent litigation remains unresolved. One case has a jury trial scheduled for April 29, 2024; another for June 9, 2025. In a separate case, the court entered judgment for AngioDynamics in June 2023 after finding asserted claims invalid; Bard’s appeal is pending. The company has not accrued for these matters because it cannot determine that a loss is probable and reasonably estimable.
- Other stated risks include competition and product development, regulatory and clinical outcomes, product liability or recalls, litigation, economic and supply-chain conditions, foreign-exchange movements, and the ability to obtain financing if needed.
Important facts for investors to verify
- How much of reported profitability and cash generation is attributable to the one-time divestiture and related tax accounting, rather than ongoing operations.
- Whether Med Tech growth can continue and Med Device margins and sales stabilize after the dialysis and BioSentry sale.
- Drivers of operating cash outflows and working-capital changes, including the elevated inventory balance.
- Future earn-out payments and developments in Bard litigation, including the scheduled trials and pending appeal.
- Management’s liquidity outlook and any need for financing if operating cash flows weaken or acquisitions are pursued.